Cell damage by excess CuZnSOD and down's syndrome

Down's Syndrome (DS), the phenotypic expression of human trisomy 21, is presumed to result from over-expression of certain genes residing on chromosome 21 at the segment 21q22-the Down locus. The “housekeeping” enzyme CuZn-superoxide dismutase (CuZnSOD) is encoded by a gene from that region and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 1994, Vol.48 (5), p.231,240-237,240
Hauptverfasser: Groner, Y., Elroy-Sterol, O., Avraham, K.B., Schickler, M., Knobler, H., Minc-Golomb, D., Bar-Peled, O., Yarom, R., Rotshenker, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 237,240
container_issue 5
container_start_page 231,240
container_title Biomedicine & pharmacotherapy
container_volume 48
creator Groner, Y.
Elroy-Sterol, O.
Avraham, K.B.
Schickler, M.
Knobler, H.
Minc-Golomb, D.
Bar-Peled, O.
Yarom, R.
Rotshenker, S.
description Down's Syndrome (DS), the phenotypic expression of human trisomy 21, is presumed to result from over-expression of certain genes residing on chromosome 21 at the segment 21q22-the Down locus. The “housekeeping” enzyme CuZn-superoxide dismutase (CuZnSOD) is encoded by a gene from that region and its activity is elevated in DS patients. Moreover, the recent discovery that familial ALS is associated with mutations in the gene encoding CuZnSOD, focused attention on the entanglement of oxygen-free radicals in cell death and neuronal disorders. To investigate the involvement of CuZnSOD gene dosage in the etiology of the syndrome we have developed both cellular and animal models which enabled us to investigate the physiological consequences resulting from overexpression of the CuZnSOD gene. Rat PC12 cells expressing elevated levels of transfected human CuZnSOD gene were generated. These transformants (designated PC12-hSOD) closely resembled the parental cells in their morphology, growth rate, and response to nerve growth factor, but showed impaired neurotransmitter uptake. The lesion was localized to the chromaffin granule transport mechanism. These results show that elevation of CuZnSOD activity interferes with the transport of biogenic amines into chromaffin granules. Since neurotransmitter uptake plays an important role in many processes of the central nervous system, CuZnSOD gene-dosage may contribute to the neurobiological abnormalities of Down's Syndrome. As an approach to the development of an animal model for Down's Syndrome, several strains of transgenic mice which carry the human CuZnSOD gene have been prepared. These animals express the transgene as an active enzyme with increased activity from 1.6 to 6.0-fold in the brains of four transgenic strains and to an equal or lesser extent in several other tissues. To investigate the contribution of CuZnSOD gene dosage in the neuropathological symptoms of Down's Syndrome, we analyzed the tongue muscle of the transgenic-CuZnSOD mice. The tongue neuromuscular junctions (NMJ) in the transgenic animals exhibited significant pathological changes; withdrawal and destruction of some terminal axons and the development of multiple small terminals. The ratio of terminal axon area to postsynaptic membranes decreased, and secondary folds were often complex and hyperplastic. The morphological changes in the transgenic NMJ were similar to those previously seen in the transgenic NMJ and were similar to those previously seen
doi_str_mv 10.1016/0753-3322(94)90138-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76894852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0753332294901384</els_id><sourcerecordid>76894852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-e5a25adce3c83e4dc6583304e309ae8650604e723a475647c599f4d24f05d9af3</originalsourceid><addsrcrecordid>eNp9kEtLw0AQxxdRaq1-A4WcfByik-z7Ikh8QqEH9eJl2e5OJNIkdbdR--1NbenRuQzD_z-vHyHHGVxmkIkrkJymlOb5uWYXGjKqUrZDhpnmkAoAuUuGW8s-OYjxAwC4oGpABlL3odiQZAXOZom3tX3HZLpM8MdhjEnRvTXPk9vENj7x7XdzFpO4bHxoazwke6WdRTza5BF5vb97KR7T8eThqbgZp45yuUiR25xb75A6RZF5J7iiFBhS0BaV4CD6QubUMskFk45rXTKfsxK417akI3K6njsP7WeHcWHqKrr-Wttg20UjhdJM8bw3srXRhTbGgKWZh6q2YWkyMCtSZoXBrDAYzcwfKcP6tpPN_G5ao982bdD0-vVax_7JrwqDia7CxqGvArqF8W31_4Jfqnp1Wg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76894852</pqid></control><display><type>article</type><title>Cell damage by excess CuZnSOD and down's syndrome</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Groner, Y. ; Elroy-Sterol, O. ; Avraham, K.B. ; Schickler, M. ; Knobler, H. ; Minc-Golomb, D. ; Bar-Peled, O. ; Yarom, R. ; Rotshenker, S.</creator><creatorcontrib>Groner, Y. ; Elroy-Sterol, O. ; Avraham, K.B. ; Schickler, M. ; Knobler, H. ; Minc-Golomb, D. ; Bar-Peled, O. ; Yarom, R. ; Rotshenker, S.</creatorcontrib><description>Down's Syndrome (DS), the phenotypic expression of human trisomy 21, is presumed to result from over-expression of certain genes residing on chromosome 21 at the segment 21q22-the Down locus. The “housekeeping” enzyme CuZn-superoxide dismutase (CuZnSOD) is encoded by a gene from that region and its activity is elevated in DS patients. Moreover, the recent discovery that familial ALS is associated with mutations in the gene encoding CuZnSOD, focused attention on the entanglement of oxygen-free radicals in cell death and neuronal disorders. To investigate the involvement of CuZnSOD gene dosage in the etiology of the syndrome we have developed both cellular and animal models which enabled us to investigate the physiological consequences resulting from overexpression of the CuZnSOD gene. Rat PC12 cells expressing elevated levels of transfected human CuZnSOD gene were generated. These transformants (designated PC12-hSOD) closely resembled the parental cells in their morphology, growth rate, and response to nerve growth factor, but showed impaired neurotransmitter uptake. The lesion was localized to the chromaffin granule transport mechanism. These results show that elevation of CuZnSOD activity interferes with the transport of biogenic amines into chromaffin granules. Since neurotransmitter uptake plays an important role in many processes of the central nervous system, CuZnSOD gene-dosage may contribute to the neurobiological abnormalities of Down's Syndrome. As an approach to the development of an animal model for Down's Syndrome, several strains of transgenic mice which carry the human CuZnSOD gene have been prepared. These animals express the transgene as an active enzyme with increased activity from 1.6 to 6.0-fold in the brains of four transgenic strains and to an equal or lesser extent in several other tissues. To investigate the contribution of CuZnSOD gene dosage in the neuropathological symptoms of Down's Syndrome, we analyzed the tongue muscle of the transgenic-CuZnSOD mice. The tongue neuromuscular junctions (NMJ) in the transgenic animals exhibited significant pathological changes; withdrawal and destruction of some terminal axons and the development of multiple small terminals. The ratio of terminal axon area to postsynaptic membranes decreased, and secondary folds were often complex and hyperplastic. The morphological changes in the transgenic NMJ were similar to those previously seen in the transgenic NMJ and were similar to those previously seen in muscles of aging mice and rats as well as in tongue muscles of patients with Down's Syndrome. The findings suggest that CuZnSOD gene dosage is involved in the pathological abnormalities of tongue NMJ observed in Down's Syndrome patients. Reduced levels of the neurotransmitter serotonin in blood platelets is a clinical symptom characteristic of individuals with Down's Syndrome. To investigate the possible involvement of the CuZnSOD gene, in the etiology of that symptom, we examined blood platelets of the transgenic mice harboring the human CuZnSOD gene. It was found that platelets of transgenic CuZnSOD animals which overexpress the transgene contain lower levels of serotonin, due to a reduced rate of uptake of the neurotransmitter by the dense granules of the platelets. Furthermore, significantly lower than normal serotonin accumulation rate was also detected in dense granules isolated from blood platelets of DS individuals. These findings suggest that CuZnSOD gene dosage affects the dense granule transport system and is thereby involved in the depressed level of blood serotonin found in patients born with Down's Syndrome.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/0753-3322(94)90138-4</identifier><identifier>PMID: 7999984</identifier><language>eng</language><publisher>France: Elsevier SAS</publisher><subject>Animals ; Cells, Cultured ; Down Syndrome - blood ; Down Syndrome - enzymology ; Down Syndrome - genetics ; Down Syndrome - pathology ; Down's Syndrome ; excess CuZnSOD ; Mice ; Mice, Transgenic ; Phenotype ; Serotonin - blood ; Superoxide Dismutase - genetics ; Superoxide Dismutase - metabolism ; transfected cells ; Transfection</subject><ispartof>Biomedicine &amp; pharmacotherapy, 1994, Vol.48 (5), p.231,240-237,240</ispartof><rights>1994</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-e5a25adce3c83e4dc6583304e309ae8650604e723a475647c599f4d24f05d9af3</citedby><cites>FETCH-LOGICAL-c357t-e5a25adce3c83e4dc6583304e309ae8650604e723a475647c599f4d24f05d9af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0753332294901384$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,4009,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7999984$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Groner, Y.</creatorcontrib><creatorcontrib>Elroy-Sterol, O.</creatorcontrib><creatorcontrib>Avraham, K.B.</creatorcontrib><creatorcontrib>Schickler, M.</creatorcontrib><creatorcontrib>Knobler, H.</creatorcontrib><creatorcontrib>Minc-Golomb, D.</creatorcontrib><creatorcontrib>Bar-Peled, O.</creatorcontrib><creatorcontrib>Yarom, R.</creatorcontrib><creatorcontrib>Rotshenker, S.</creatorcontrib><title>Cell damage by excess CuZnSOD and down's syndrome</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Down's Syndrome (DS), the phenotypic expression of human trisomy 21, is presumed to result from over-expression of certain genes residing on chromosome 21 at the segment 21q22-the Down locus. The “housekeeping” enzyme CuZn-superoxide dismutase (CuZnSOD) is encoded by a gene from that region and its activity is elevated in DS patients. Moreover, the recent discovery that familial ALS is associated with mutations in the gene encoding CuZnSOD, focused attention on the entanglement of oxygen-free radicals in cell death and neuronal disorders. To investigate the involvement of CuZnSOD gene dosage in the etiology of the syndrome we have developed both cellular and animal models which enabled us to investigate the physiological consequences resulting from overexpression of the CuZnSOD gene. Rat PC12 cells expressing elevated levels of transfected human CuZnSOD gene were generated. These transformants (designated PC12-hSOD) closely resembled the parental cells in their morphology, growth rate, and response to nerve growth factor, but showed impaired neurotransmitter uptake. The lesion was localized to the chromaffin granule transport mechanism. These results show that elevation of CuZnSOD activity interferes with the transport of biogenic amines into chromaffin granules. Since neurotransmitter uptake plays an important role in many processes of the central nervous system, CuZnSOD gene-dosage may contribute to the neurobiological abnormalities of Down's Syndrome. As an approach to the development of an animal model for Down's Syndrome, several strains of transgenic mice which carry the human CuZnSOD gene have been prepared. These animals express the transgene as an active enzyme with increased activity from 1.6 to 6.0-fold in the brains of four transgenic strains and to an equal or lesser extent in several other tissues. To investigate the contribution of CuZnSOD gene dosage in the neuropathological symptoms of Down's Syndrome, we analyzed the tongue muscle of the transgenic-CuZnSOD mice. The tongue neuromuscular junctions (NMJ) in the transgenic animals exhibited significant pathological changes; withdrawal and destruction of some terminal axons and the development of multiple small terminals. The ratio of terminal axon area to postsynaptic membranes decreased, and secondary folds were often complex and hyperplastic. The morphological changes in the transgenic NMJ were similar to those previously seen in the transgenic NMJ and were similar to those previously seen in muscles of aging mice and rats as well as in tongue muscles of patients with Down's Syndrome. The findings suggest that CuZnSOD gene dosage is involved in the pathological abnormalities of tongue NMJ observed in Down's Syndrome patients. Reduced levels of the neurotransmitter serotonin in blood platelets is a clinical symptom characteristic of individuals with Down's Syndrome. To investigate the possible involvement of the CuZnSOD gene, in the etiology of that symptom, we examined blood platelets of the transgenic mice harboring the human CuZnSOD gene. It was found that platelets of transgenic CuZnSOD animals which overexpress the transgene contain lower levels of serotonin, due to a reduced rate of uptake of the neurotransmitter by the dense granules of the platelets. Furthermore, significantly lower than normal serotonin accumulation rate was also detected in dense granules isolated from blood platelets of DS individuals. These findings suggest that CuZnSOD gene dosage affects the dense granule transport system and is thereby involved in the depressed level of blood serotonin found in patients born with Down's Syndrome.</description><subject>Animals</subject><subject>Cells, Cultured</subject><subject>Down Syndrome - blood</subject><subject>Down Syndrome - enzymology</subject><subject>Down Syndrome - genetics</subject><subject>Down Syndrome - pathology</subject><subject>Down's Syndrome</subject><subject>excess CuZnSOD</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Phenotype</subject><subject>Serotonin - blood</subject><subject>Superoxide Dismutase - genetics</subject><subject>Superoxide Dismutase - metabolism</subject><subject>transfected cells</subject><subject>Transfection</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLw0AQxxdRaq1-A4WcfByik-z7Ikh8QqEH9eJl2e5OJNIkdbdR--1NbenRuQzD_z-vHyHHGVxmkIkrkJymlOb5uWYXGjKqUrZDhpnmkAoAuUuGW8s-OYjxAwC4oGpABlL3odiQZAXOZom3tX3HZLpM8MdhjEnRvTXPk9vENj7x7XdzFpO4bHxoazwke6WdRTza5BF5vb97KR7T8eThqbgZp45yuUiR25xb75A6RZF5J7iiFBhS0BaV4CD6QubUMskFk45rXTKfsxK417akI3K6njsP7WeHcWHqKrr-Wttg20UjhdJM8bw3srXRhTbGgKWZh6q2YWkyMCtSZoXBrDAYzcwfKcP6tpPN_G5ao982bdD0-vVax_7JrwqDia7CxqGvArqF8W31_4Jfqnp1Wg</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>Groner, Y.</creator><creator>Elroy-Sterol, O.</creator><creator>Avraham, K.B.</creator><creator>Schickler, M.</creator><creator>Knobler, H.</creator><creator>Minc-Golomb, D.</creator><creator>Bar-Peled, O.</creator><creator>Yarom, R.</creator><creator>Rotshenker, S.</creator><general>Elsevier SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1994</creationdate><title>Cell damage by excess CuZnSOD and down's syndrome</title><author>Groner, Y. ; Elroy-Sterol, O. ; Avraham, K.B. ; Schickler, M. ; Knobler, H. ; Minc-Golomb, D. ; Bar-Peled, O. ; Yarom, R. ; Rotshenker, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-e5a25adce3c83e4dc6583304e309ae8650604e723a475647c599f4d24f05d9af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Animals</topic><topic>Cells, Cultured</topic><topic>Down Syndrome - blood</topic><topic>Down Syndrome - enzymology</topic><topic>Down Syndrome - genetics</topic><topic>Down Syndrome - pathology</topic><topic>Down's Syndrome</topic><topic>excess CuZnSOD</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Phenotype</topic><topic>Serotonin - blood</topic><topic>Superoxide Dismutase - genetics</topic><topic>Superoxide Dismutase - metabolism</topic><topic>transfected cells</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Groner, Y.</creatorcontrib><creatorcontrib>Elroy-Sterol, O.</creatorcontrib><creatorcontrib>Avraham, K.B.</creatorcontrib><creatorcontrib>Schickler, M.</creatorcontrib><creatorcontrib>Knobler, H.</creatorcontrib><creatorcontrib>Minc-Golomb, D.</creatorcontrib><creatorcontrib>Bar-Peled, O.</creatorcontrib><creatorcontrib>Yarom, R.</creatorcontrib><creatorcontrib>Rotshenker, S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Groner, Y.</au><au>Elroy-Sterol, O.</au><au>Avraham, K.B.</au><au>Schickler, M.</au><au>Knobler, H.</au><au>Minc-Golomb, D.</au><au>Bar-Peled, O.</au><au>Yarom, R.</au><au>Rotshenker, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cell damage by excess CuZnSOD and down's syndrome</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>1994</date><risdate>1994</risdate><volume>48</volume><issue>5</issue><spage>231,240</spage><epage>237,240</epage><pages>231,240-237,240</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Down's Syndrome (DS), the phenotypic expression of human trisomy 21, is presumed to result from over-expression of certain genes residing on chromosome 21 at the segment 21q22-the Down locus. The “housekeeping” enzyme CuZn-superoxide dismutase (CuZnSOD) is encoded by a gene from that region and its activity is elevated in DS patients. Moreover, the recent discovery that familial ALS is associated with mutations in the gene encoding CuZnSOD, focused attention on the entanglement of oxygen-free radicals in cell death and neuronal disorders. To investigate the involvement of CuZnSOD gene dosage in the etiology of the syndrome we have developed both cellular and animal models which enabled us to investigate the physiological consequences resulting from overexpression of the CuZnSOD gene. Rat PC12 cells expressing elevated levels of transfected human CuZnSOD gene were generated. These transformants (designated PC12-hSOD) closely resembled the parental cells in their morphology, growth rate, and response to nerve growth factor, but showed impaired neurotransmitter uptake. The lesion was localized to the chromaffin granule transport mechanism. These results show that elevation of CuZnSOD activity interferes with the transport of biogenic amines into chromaffin granules. Since neurotransmitter uptake plays an important role in many processes of the central nervous system, CuZnSOD gene-dosage may contribute to the neurobiological abnormalities of Down's Syndrome. As an approach to the development of an animal model for Down's Syndrome, several strains of transgenic mice which carry the human CuZnSOD gene have been prepared. These animals express the transgene as an active enzyme with increased activity from 1.6 to 6.0-fold in the brains of four transgenic strains and to an equal or lesser extent in several other tissues. To investigate the contribution of CuZnSOD gene dosage in the neuropathological symptoms of Down's Syndrome, we analyzed the tongue muscle of the transgenic-CuZnSOD mice. The tongue neuromuscular junctions (NMJ) in the transgenic animals exhibited significant pathological changes; withdrawal and destruction of some terminal axons and the development of multiple small terminals. The ratio of terminal axon area to postsynaptic membranes decreased, and secondary folds were often complex and hyperplastic. The morphological changes in the transgenic NMJ were similar to those previously seen in the transgenic NMJ and were similar to those previously seen in muscles of aging mice and rats as well as in tongue muscles of patients with Down's Syndrome. The findings suggest that CuZnSOD gene dosage is involved in the pathological abnormalities of tongue NMJ observed in Down's Syndrome patients. Reduced levels of the neurotransmitter serotonin in blood platelets is a clinical symptom characteristic of individuals with Down's Syndrome. To investigate the possible involvement of the CuZnSOD gene, in the etiology of that symptom, we examined blood platelets of the transgenic mice harboring the human CuZnSOD gene. It was found that platelets of transgenic CuZnSOD animals which overexpress the transgene contain lower levels of serotonin, due to a reduced rate of uptake of the neurotransmitter by the dense granules of the platelets. Furthermore, significantly lower than normal serotonin accumulation rate was also detected in dense granules isolated from blood platelets of DS individuals. These findings suggest that CuZnSOD gene dosage affects the dense granule transport system and is thereby involved in the depressed level of blood serotonin found in patients born with Down's Syndrome.</abstract><cop>France</cop><pub>Elsevier SAS</pub><pmid>7999984</pmid><doi>10.1016/0753-3322(94)90138-4</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 1994, Vol.48 (5), p.231,240-237,240
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_76894852
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Cells, Cultured
Down Syndrome - blood
Down Syndrome - enzymology
Down Syndrome - genetics
Down Syndrome - pathology
Down's Syndrome
excess CuZnSOD
Mice
Mice, Transgenic
Phenotype
Serotonin - blood
Superoxide Dismutase - genetics
Superoxide Dismutase - metabolism
transfected cells
Transfection
title Cell damage by excess CuZnSOD and down's syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T03%3A53%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cell%20damage%20by%20excess%20CuZnSOD%20and%20down's%20syndrome&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Groner,%20Y.&rft.date=1994&rft.volume=48&rft.issue=5&rft.spage=231,240&rft.epage=237,240&rft.pages=231,240-237,240&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/0753-3322(94)90138-4&rft_dat=%3Cproquest_cross%3E76894852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76894852&rft_id=info:pmid/7999984&rft_els_id=0753332294901384&rfr_iscdi=true